| Category | Summary |
|---|---|
| Identity/synonyms | - **ARNT** is the human **aryl hydrocarbon receptor nuclear translocator**, synonymous with **HIF-1β/HIF1B** and classified as a **class II bHLH-PAS transcription factor**.  - It is the obligate partner for several class I bHLH-PAS proteins, matching UniProt P27540 identity and nomenclature. (pqac-00000009, pqac-00000018) |
| Domains | - Conserved architecture includes an **N-terminal bHLH DNA-binding/dimerization domain**, tandem **PAS-A** and **PAS-B** domains, and a **C-terminal transactivation region/TAD** that is largely disordered in structural studies.  - In AHR complexes, **PAS-A** helps specify/stabilize heterodimerization, while **PAS-B** can participate in higher-order interface formation. (pqac-00000017, pqac-00000018, pqac-00000020) |
| Core molecular function | - ARNT functions primarily as a **heterodimeric transcription-factor scaffold/partner**, enabling DNA binding and transcriptional activation by AHR and HIF-α proteins rather than acting as an enzyme or transporter.  - In hypoxia, ARNT is required for HIF-dependent activation of hypoxia-responsive genes; in xenobiotic signaling, it forms the active **AHR-ARNT** complex. (pqac-00000010, pqac-00000017, pqac-00000020) |
| Key heterodimer partners | - Best-established partners are **AHR**, **HIF-1α**, and **HIF-2α**; additional literature also notes interactions with **SIM proteins** and crosstalk/competition involving **ER** and **AhRR** in pathway regulation.  - ARNT-containing complexes are structurally distinct from BMAL1-containing bHLH-PAS complexes. (pqac-00000013, pqac-00000015, pqac-00000018) |
| DNA response elements | - In **HIF** signaling, HIF-α/ARNT heterodimers bind **hypoxia response elements (HREs)** to induce genes such as **VEGF** and **erythropoietin**.  - In **AHR** signaling, AHR-ARNT binds **xenobiotic response elements (XREs/DREs)**; the AhR bHLH domain recognizes the canonical **XRE consensus TTGCGTG**. (pqac-00000009, pqac-00000020) |
| Subcellular localization/transport | - ARNT is mainly described as a **nuclear protein**.  - In the AHR pathway, ligand-bound AHR translocates from the cytoplasm to the nucleus and then heterodimerizes with ARNT; structural work supports a transition from chaperone-bound AHR to a nuclear AHR-ARNT transcriptional complex.  - Ullah et al. also notes ARNT contains a **nuclear localization signal** and mediates nuclear translocation of ligand-bound AHR. (pqac-00000013, pqac-00000015, pqac-00000017) |
| Representative target genes/programs | - **AHR-ARNT** drives detoxification and immune-response programs, including canonical CYP genes such as **CYP1A1, CYP1A2, CYP1B1**.  - **HIF-α/ARNT** drives hypoxia-adaptation programs including **angiogenesis, endothelial survival/barrier integrity, anaerobic metabolism**, and induction of **VEGF** and **EPO**. (pqac-00000010, pqac-00000020, pqac-00000021) |
| Recent 2023-2024 developments | - **2023 review:** endothelial ARNT was highlighted as crucial for angiogenesis, anti-inflammatory signaling, redox control, and cardiovascular protection in ischemic heart disease models.  - **2024 review:** AhR-ARNT structural/functional work emphasized domain-specific control of XRE recognition and heterodimer stability.  - **2024 GBM study:** ARNT was shown to bind **p38α** via its **PAS-A domain**, stabilizing p38/MAPK signaling and promoting chemoresistance. (pqac-00000013, pqac-00000020, pqac-00000024, pqac-00000025) |
| Translational relevance/applications | - ARNT is relevant to **hypoxia biology**, **environmental toxicology**, **inflammation**, **cardiovascular disease**, and **cancer**.  - In GBM, disrupting the **ARNT-p38α** interaction restored **temozolomide sensitivity**, supporting ARNT as a therapeutic target.  - In AHR pharmacology, the approved AHR agonist **tapinarof** underscores the therapeutic importance of the AHR-ARNT axis. (pqac-00000023, pqac-00000025, pqac-00000017, pqac-00000000) |
| Quantitative/statistical notes | - GBM has a reported **median survival of ~15 months**, and standard therapy improved median survival only from **~12 to 16 months**; ARNT was reported as **upregulated in GBM** and associated with **poorer survival** and mesenchymal subtype.  - In mouse development, loss of endothelial ARNT caused severe cardiovascular/vascular defects, with **nearly 90%** of embryos reportedly not surviving beyond **E10.5** in one cited study.  - Open Targets shows ARNT disease associations across **melanoma, neurodegenerative disease, breast ductal adenocarcinoma, and endometrioid adenocarcinomas**. (pqac-00000023, pqac-00000025, pqac-00000026, pqac-00000000) |


*Table: This table summarizes verified functional annotation for human ARNT (UniProt P27540), including domains, molecular role, pathway context, localization, and translational relevance. It condenses the most useful evidence for rapid reference while preserving source citations.*